JANE STREET GROUP, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.

Quarter-by-quarter ownership
JANE STREET GROUP, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$6,116
-73.5%
30,563
+117.5%
0.00%
Q4 2022$23,049
-30.2%
14,054
+16.3%
0.00%
Q2 2022$33,000
-57.1%
12,085
-37.4%
0.00%
Q4 2021$77,000
-25.2%
19,300
-38.1%
0.00%
Q3 2021$103,000
-48.8%
31,200
-41.1%
0.00%
Q2 2021$201,000
-47.2%
52,943
-46.9%
0.00%
Q1 2021$381,000
-65.6%
99,700
-59.3%
0.00%
Q4 2020$1,108,000
-68.7%
244,833
+17.0%
0.00%
-100.0%
Q3 2020$3,541,000
+96.8%
209,300
+30.4%
0.00%
+100.0%
Q2 2020$1,799,000
+665.5%
160,453
+216.6%
0.00%
Q1 2020$235,00050,6850.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Ikarian Capital, LLC 189,935$311,4940.08%
ABNER HERRMAN & BROCK LLC 280,000$4590.07%
Weaver Consulting Group 65,947$108,1530.06%
S.C. Financial Services, Inc. 25,372$41,6100.03%
JMAC ENTERPRISES LLC 40,430$66,3050.02%
Weaver Consulting Group 53,500$10,0470.01%
IFP Advisors, Inc 26,650$1390.00%
Bangor Savings Bank 4,000$70.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$4,9200.00%
BOOTHBAY FUND MANAGEMENT, LLC 19,098$31,3210.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders